DENTSPLY SIRONA Inc. (NASDAQ:XRAY) issued an update on its FY17 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $2.65-2.75 for the period, compared to the Thomson Reuters consensus estimate of $2.84.

Shares of DENTSPLY SIRONA Inc. (XRAY) opened at 61.41 on Wednesday. The firm’s 50 day moving average is $63.70 and its 200 day moving average is $62.23. DENTSPLY SIRONA Inc. has a 1-year low of $55.00 and a 1-year high of $65.68. The firm has a market capitalization of $14.08 billion, a PE ratio of 39.52 and a beta of 1.26.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.65 EPS for the quarter, hitting the consensus estimate of $0.65. DENTSPLY SIRONA had a net margin of 9.42% and a return on equity of 7.37%. The firm had revenue of $992.70 million for the quarter, compared to analysts’ expectations of $1 billion. During the same period in the previous year, the business earned $0.76 earnings per share. DENTSPLY SIRONA’s revenue for the quarter was down 2.9% compared to the same quarter last year. Analysts anticipate that DENTSPLY SIRONA Inc. will post $2.84 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 13th. Shareholders of record on Friday, September 29th will be issued a dividend of $0.0875 per share. The ex-dividend date is Thursday, September 28th. This represents a $0.35 annualized dividend and a yield of 0.57%. DENTSPLY SIRONA’s payout ratio is presently 22.58%.

Several analysts have issued reports on XRAY shares. BidaskClub downgraded DENTSPLY SIRONA from a hold rating to a sell rating in a report on Friday, July 28th. Cleveland Research upgraded DENTSPLY SIRONA from a neutral rating to a buy rating in a report on Tuesday, May 23rd. Goldman Sachs Group, Inc. (The) downgraded DENTSPLY SIRONA from a neutral rating to a sell rating and cut their price objective for the stock from $60.00 to $55.00 in a report on Tuesday, May 23rd. Zacks Investment Research upgraded DENTSPLY SIRONA from a sell rating to a hold rating and set a $71.00 price objective on the stock in a report on Tuesday, May 2nd. Finally, HC Wainwright started coverage on DENTSPLY SIRONA in a report on Tuesday, July 11th. They set a buy rating and a $74.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $67.92.

ILLEGAL ACTIVITY WARNING: This report was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at


DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Earnings History and Estimates for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with's FREE daily email newsletter.